Get the Stockscreener App
35.10
0.14%
-0.05
Sanara Medtech Inc stock is traded at $35.10, with a volume of 109.15K.
It is down -0.14% in the last 24 hours and up +2.09% over the past month.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
See More
Previous Close:
$35.15
Open:
$35.09
24h Volume:
109.15K
Relative Volume:
0.44
Market Cap:
$322.50M
Revenue:
$103.14M
Net Income/Loss:
$-5.82M
P/E Ratio:
-8.0641
EPS:
-4.3526
Net Cash Flow:
$2.14M
1W Performance:
+0.34%
1M Performance:
+2.09%
6M Performance:
+94.14%
1Y Performance:
+7.77%
1-Day Range:
$35.07
$35.20
1-Week Range:
$34.94
$35.34
52-Week Range:
$16.05
$35.34
Sanara Medtech Inc Stock (SMTI) Company Profile
Name
Sanara Medtech Inc
Sector
Industry
Phone
817-529-2300
Address
1200 SUMMIT AVE, FORT WORTH
Compare SMTI vs ISRG, BDX, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMTI
Sanara Medtech Inc
|
35.10 | 322.50M | 103.14M | -5.82M | 2.14M | -4.3526 |
ISRG
Intuitive Surgical Inc
|
399.52 | 141.14B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.23 | 48.82B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
221.89 | 32.01B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
64.56 | 31.21B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.66 | 30.41B | 29.14B | 1.07B | 1.05B | 1.1956 |
Sanara Medtech Inc Stock (SMTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Lake Street | Buy |
| Mar-26-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| May-20-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jun-30-21 | Initiated | Cantor Fitzgerald | Overweight |
Sanara Medtech Inc Stock (SMTI) Latest News
Sanara MedTech stock reports 9 percent revenue growth - AD HOC NEWS
Precision Trading with Sanara Medtech Inc. (SMTI) Risk Zones - news.stocktradersdaily.com
SMTI - Finviz
Sanara MedTech stock holds near its 52-week high - AD HOC NEWS
Sanara MedTech CEO Yon Seth D Forfeits 3,661 Shares at $35.11 Each - Kalkine Media
Sanara Medtech Inc (SMTI) Key Financial Ratios – Valuation, Profitability & More - Value Research
Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc.SMTI - Business Wire
MIMEDX to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Sanara MedTech Seeks Shareholder Approval for Merger With MiMedx - The Globe and Mail
[DEFM14A] Sanara MedTech Inc. Merger Proxy Statement - stocktitan.net
Why (SMTI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Sanara MedTech (SMTI) Holds Steady at $34.57 as Traders Eye Resistance at $36.30ATR Trailing Stop - dars.gov.et
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanar - The National Law Review
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
SMTI | Sanara MedTech Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc.SMTI - Eastern Progress
Sanara MedTech (SMTI) agrees to MiMedx takeover, targeting year-end close - Stock Titan
Sanara MedTech Inc. (NASDAQ:SMTI) Short Interest Update - MarketBeat
Walleye Capital LLC Makes New $719,000 Investment in Sanara MedTech Inc. $SMTI - MarketBeat
SMTI Q1 2026 Earnings: Positive EPS Surprise Overcomes Expected LossOne-Time Gain Impact - vinanet.vn
Sanara MedTech (SMTI) Stock Stays Quiet As Profitability Meets Debt Scrutiny - Sahm
(SMTI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) - The Manila Times
Sanara Medtech earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Sanara Medtech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates - Yahoo Finance
Sanara MedTech (NASDAQ:SMTI) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Sanara MedTech Q2 Results: Sales Rise 9% YoY, EPS Misses Estimate - scanx.trade
Sanara MedTech Inc. Q2 2026: Revenue $28.14M, EPS $(0.05) — 10-Q Summary - TradingView
Sanara MedTech (SMTI) grows H1 2026 revenue to $55.9M and trims loss - Stock Titan
MiMedx Group (SMTI partner) clarifies Sanara merger fees and $33 cash-plus-stock deal - Stock Titan
Form 8K Sanara Medtech Inc For: 11 August By Investing.com - Investing.com Nigeria
Sanara MedTech Corrects Termination Fees in Merger Deal with MiMedx - Kalkine Media
Sanara MedTech Inc. (SMTI) Releases Q2 2026 Earnings: Revenue Rises 8.9% - Quiver Quantitative
Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock merger terms and corrects fees - Stock Titan
Sanara MedTech Q2 revenue rises on soft-tissue product growth - TradingView
Sanara MedTech (SMTI) grows revenue, posts Q2 loss amid pending MIMEDX deal - Stock Titan
Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock per share in merger - Stock Titan
Sanara MedTech, Inc. (SMTI) Investigation: Bronstein, Gewirtz & G - The National Law Review
Sanara Medtech Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Sanara MedTech Inc. (NASDAQ:SMTI) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTec - The National Law Review
Sanara MedTech (SMTI) Expected to Post Earnings on Wednesday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech, Inc - The National Law Review
Sanara MedTech (NASDAQ:SMTI) Stock Rating Lowered by Freedom Capital - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
How (SMTI) Movements Inform Risk Allocation Models - Stock Traders Daily
Sanara MedTech (SMTI) Holds Near $33.86 as Support Levels Come into FocusRSI Oversold Picks - siam.in
SANARA MEDTECH INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY; CUTS TARGET PRICE TO $35 FROM $36 - webull.com
Mimedx to buy Sanara for $350M to move beyond wound care - bioworld.com
Sanara Medtech Inc Stock (SMTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
3.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):